Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02907177




Registration number
NCT02907177
Ethics application status
Date submitted
25/08/2016
Date registered
20/09/2016
Date last updated
18/05/2021

Titles & IDs
Public title
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
Scientific title
Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
Secondary ID [1] 0 0
AC-058B302
Universal Trial Number (UTN)
Trial acronym
POINT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ponesimod
Other interventions - Placebo

Experimental: Ponesimod - Ponesimod

Placebo Comparator: Placebo - Placebo


Treatment: Drugs: Ponesimod
One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).

Other interventions: Placebo
One tablet of matching placebo administered orally once daily in the morning
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Confirmed Relapse Rate (ARR)
Timepoint [1] 0 0
Through study completion, an average of 68 weeks
Secondary outcome [1] 0 0
Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96
Timepoint [1] 0 0
Week 96
Secondary outcome [2] 0 0
Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96
Timepoint [2] 0 0
Week 96
Secondary outcome [3] 0 0
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
Timepoint [3] 0 0
Up to 147 Weeks

Eligibility
Key inclusion criteria
- Signed informed consent prior to initiation of any study-mandated procedure.

- Women of childbearing potential must have a negative pregnancy test and use reliable
methods of contraception

- Presenting with a diagnosis of MS as defined by the revised (2010) McDonald Diagnostic
Criteria for MS with relapsing course from onset (i.e., relapsing-remitting multiple
sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) with superimposed
relapses).

- Ongoing treatment with DMF for at least 6 months prior to screening

- Active disease after at least 3 months of DMF treatment

- Ambulatory and with an EDSS score between 0 and 6.0 (inclusive).
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Lactating or pregnant women and women intending to become pregnant during the study.

- Presenting with a diagnosis of MS with progressive course from onset (i.e., primary
progressive MS or progressive relapsing MS).

- Evidence of a relapse of MS with onset within 30 days prior to baseline EDSS
assessment.

- Any circumstances or conditions, which, in the opinion of the investigator, may affect
full participation in the study or compliance with the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/03/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/03/2020
Sample size
Target
Accrual to date
Final
136
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Health - Neuro-Immunology Clinical Research, Education and Support Service - Heidelberg
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
New Mexico
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussels
Country [18] 0 0
Belgium
State/province [18] 0 0
Gent
Country [19] 0 0
Belgium
State/province [19] 0 0
Overpelt
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofia
Country [21] 0 0
Canada
State/province [21] 0 0
Edmonton
Country [22] 0 0
Czechia
State/province [22] 0 0
Brno
Country [23] 0 0
Czechia
State/province [23] 0 0
Hradec Králové
Country [24] 0 0
Czechia
State/province [24] 0 0
Jihlava
Country [25] 0 0
Czechia
State/province [25] 0 0
Pardubice
Country [26] 0 0
Czechia
State/province [26] 0 0
Teplice
Country [27] 0 0
Denmark
State/province [27] 0 0
Aalborg
Country [28] 0 0
Denmark
State/province [28] 0 0
Glostrup
Country [29] 0 0
France
State/province [29] 0 0
Bobigny
Country [30] 0 0
France
State/province [30] 0 0
Clermont Ferrand
Country [31] 0 0
France
State/province [31] 0 0
Corbeil-Essonnes
Country [32] 0 0
France
State/province [32] 0 0
Dijon
Country [33] 0 0
France
State/province [33] 0 0
Lille
Country [34] 0 0
France
State/province [34] 0 0
Montpellier
Country [35] 0 0
France
State/province [35] 0 0
Nancy
Country [36] 0 0
France
State/province [36] 0 0
Nimes
Country [37] 0 0
France
State/province [37] 0 0
Poissy
Country [38] 0 0
France
State/province [38] 0 0
Rennes
Country [39] 0 0
France
State/province [39] 0 0
Rouen
Country [40] 0 0
Germany
State/province [40] 0 0
Bad Homburg
Country [41] 0 0
Germany
State/province [41] 0 0
Dresden
Country [42] 0 0
Germany
State/province [42] 0 0
Erfurt
Country [43] 0 0
Germany
State/province [43] 0 0
Giessen
Country [44] 0 0
Germany
State/province [44] 0 0
Greifswald
Country [45] 0 0
Germany
State/province [45] 0 0
Hannover
Country [46] 0 0
Germany
State/province [46] 0 0
Leipzig
Country [47] 0 0
Germany
State/province [47] 0 0
Münster
Country [48] 0 0
Germany
State/province [48] 0 0
Siegen
Country [49] 0 0
Germany
State/province [49] 0 0
Ulm
Country [50] 0 0
Germany
State/province [50] 0 0
Westerstede
Country [51] 0 0
Greece
State/province [51] 0 0
Athens
Country [52] 0 0
Greece
State/province [52] 0 0
Marousi
Country [53] 0 0
Greece
State/province [53] 0 0
Thessaloniki
Country [54] 0 0
Hungary
State/province [54] 0 0
Budapest
Country [55] 0 0
Hungary
State/province [55] 0 0
Esztergom
Country [56] 0 0
Hungary
State/province [56] 0 0
Kistarcsa
Country [57] 0 0
Italy
State/province [57] 0 0
Cefalù
Country [58] 0 0
Italy
State/province [58] 0 0
Firenze
Country [59] 0 0
Italy
State/province [59] 0 0
Genova
Country [60] 0 0
Italy
State/province [60] 0 0
Milano
Country [61] 0 0
Italy
State/province [61] 0 0
Napoli
Country [62] 0 0
Italy
State/province [62] 0 0
Orbassano
Country [63] 0 0
Italy
State/province [63] 0 0
Pozzilli
Country [64] 0 0
Italy
State/province [64] 0 0
Roma
Country [65] 0 0
Italy
State/province [65] 0 0
Siena
Country [66] 0 0
Mexico
State/province [66] 0 0
DF
Country [67] 0 0
Mexico
State/province [67] 0 0
Jalisco
Country [68] 0 0
Mexico
State/province [68] 0 0
Monterrey
Country [69] 0 0
Mexico
State/province [69] 0 0
Chihuahua
Country [70] 0 0
Poland
State/province [70] 0 0
Bialystok
Country [71] 0 0
Poland
State/province [71] 0 0
Bydgoszcz
Country [72] 0 0
Poland
State/province [72] 0 0
Gdansk
Country [73] 0 0
Poland
State/province [73] 0 0
Katowice
Country [74] 0 0
Poland
State/province [74] 0 0
Konstancin-Jeziorna
Country [75] 0 0
Poland
State/province [75] 0 0
Ksawerów
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Poland
State/province [77] 0 0
Wroclaw
Country [78] 0 0
Portugal
State/province [78] 0 0
Lisboa
Country [79] 0 0
Portugal
State/province [79] 0 0
Porto
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Chelyabinsk
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Krasnodar
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Moscow
Country [83] 0 0
Spain
State/province [83] 0 0
Barcelona
Country [84] 0 0
Spain
State/province [84] 0 0
El Palmar
Country [85] 0 0
Spain
State/province [85] 0 0
Madrid
Country [86] 0 0
Spain
State/province [86] 0 0
Salt
Country [87] 0 0
Spain
State/province [87] 0 0
Santiago de Compostela
Country [88] 0 0
Spain
State/province [88] 0 0
Sevilla
Country [89] 0 0
Switzerland
State/province [89] 0 0
Basel
Country [90] 0 0
Switzerland
State/province [90] 0 0
Lugano
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Oxford
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Sheffield
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Stoke-on-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Actelion
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod
vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
Trial website
https://clinicaltrials.gov/ct2/show/NCT02907177
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tatiana Scherz, MD, PhD
Address 0 0
Actelion
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02907177